Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Clin Dev Immunol. 2012;2012:692639. doi: 10.1155/2012/692639. Epub 2012 Apr 10.

Releasing the brake: targeting Cbl-b to enhance lymphocyte effector functions.

Author information

1
Department of Internal Medicine V-Hematology and Oncology, Medical University Innsbruck, 6020 Innsbruck, Austria.

Abstract

The E3 ubiquitin ligase Cbl-b is an established nonredundant negative regulator of T-cell activation. Cbl-b fine-tunes the activation threshold of T cells and uncouples T cells from their vital need of a costimulatory signal to mount a productive immune response. Accordingly, mice deficient in cblb are prone to autoimmunity and reject tumors. The latter has been described to be mediated via CD8(+) T cells, which are hyperactive and more abundant in shrinking tumors of cblb-deficient animals. This might at least also in part be mediated by resistance of cblb-deficient T cells to negative cues exerted by tumor-associated immuno-suppressive factors, such as TGF-β and regulatory T cells (Treg). Experiments using cblb-deficient T cells either alone or in combination with vaccines validate the therapeutic concept of enhancing the efficacy of adoptively transferred lymphocytes to treat malignant tumors. This paper summarizes the current knowledge about the negative regulatory role of Cbl-b in T-cell activation and its potential therapeutic implications for cancer immunotherapy.

PMID:
22550535
PMCID:
PMC3328896
DOI:
10.1155/2012/692639
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Publishing Corporation Icon for PubMed Central
Loading ...
Support Center